Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: A Children's Cancer Group report

Cancer

Volumn 85, Issue 8, 1999, Pages 1859-1865

  Kaleita, Thomas A ^a,f   Reaman, Gregory H ^b   Maclean, William E ^c   Sather, Harland N ^d   Whitt, J Kenneth ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF WYOMING   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Acute lymphoblastic leukemia; Infant acute lymphoblastic leukemia; Neurodevelopmental outcome; Very high dose methotrexate

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COGNITION; EDUCATION; FEMALE; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR PERFORMANCE; NERVOUS SYSTEM DEVELOPMENT; OCCUPATION; PARENTAL BEHAVIOR; PRIORITY JOURNAL; RISK ASSESSMENT;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BRAIN DAMAGE, CHRONIC; COGNITION DISORDERS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYTARABINE; DAUNORUBICIN; DEVELOPMENTAL DISABILITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INJECTIONS, SPINAL; LEUCOVORIN; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIC INFILTRATION; MALE; METHOTREXATE; MOVEMENT DISORDERS; NEUROPSYCHOLOGICAL TESTS; PREDNISONE; PSYCHOMOTOR PERFORMANCE; REMISSION INDUCTION; RISK; SOCIOECONOMIC FACTORS; SURVIVORS; VINCRISTINE;

EID: 0033561095     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990415)85:8<1859::AID-CNCR28>3.0.CO;2-2     Document Type: Article

References (28)

1. Reaman G, Zeltzer P, Bleyer WA, Amendola B, Level C, Sather H, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Childrens Cancer Study Group. J Clin Oncol 1985;3:1513-21.
2. Heerema NA, Arthur DC, Sather H, Albo V, Feusner J, Lange BJ, et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 break point on outcome: a report of the Children's Cancer Group. Blood 1994;83:2274-84.
3. Reaman GH, Steinherz PG, Gaynon PS, Bleyer WA, Finklestein JZ, Evans R, et al. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multi-agent chemotherapy. Cancer Treat Rep 1987;71:1033-8.
4. Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry-Eaton M, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 1997;19:35-42.
5. Chessells JM, Eden OB, Bailey CC, Lilleyman JS, Richards SM. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on childhood leukaemia. Leukemia 1994;8: 1275-9.
6. Silverman LB, McLean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ, et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer 1997;80:2285-95.
7. Ferster A, Bertrand Y, Benoit Y, Boilletot A, Behar C, Margueritte G, et al. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 1994;86:284-90.
8. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999;77:445-55.
9. McCarthy DA. Manual for the McCarthy Scales of Children's Abilities. San Antonio, TX: The Psychological Corporation, 1972.
10. Kaufman AS, Kaufman NL. K-ABC: Kaufman Assessment Battery for Children. Circle Pines, MN: American Guidance Service, 1983.
11. Thorndike RL, Hagen EP, Sattler JM. Guide for administration and scoring: the Stanford-Binet Intelligence Scale. 4th ed. Chicago, IL: Riverside Publishing, 1986.
12. Wechsler D. WISC III: Wechsler Intelligence Scale for Children. 3rd ed manual. San Antonio, TX: The Psychological Corporation, 1991.
13. Stevens G, Featherman D. A revised socioeconomic index of occupational status. Soc Sci Res 1981;10:364-95.
14. Sather H, Miller D, Nesbit M, Heyn R, Hammond D. Differences in prognosis for boys and girls with acute lymphoblastic leukemia. Lancet 1981;1:739-44.
15. Hammond D, Sather H, Nesbit M, Miller D, Coccia P, Bleyer WA, et al. Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 1986;14:124-34.
16. Robison LL, Meadows AT, Nesbit ME, Ortega JA, Sather HN, Hammond GD. Factors associated with IQ scores in long-term survivors of childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1984;6:115-21.
17. Bleyer WA, Fallavollita J, Robison L, Balsam W, Meadows A, Heyn R, et al. Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial radiation during childhood: a report from the Children's Cancer Study Group. Pediatr Hematol Oncol 1990;7: 329-38.
18. Waber DP, Urion DK, Tarbell NJ, Niemeyer N, Gelber R, Sallan S. Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol 1990;32:238-48.
19. Poplack DG, Reaman GH, Bleyer WA, Miser J, Feusner J, Lesley R, et al. Central nervous system (CNS) preventive therapy with high dose methotrexate (HDMTX) in acute lymphoblastic leukemia (ALL): a preliminary report. Proc Am Soc Clin Oncol 1984;3:204.
20. Balis FM, Savitch JL, Bleyer WA, Reaman GH, Poplack DG. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985;3:485-9.
21. Brouwers P, Moss H, Reaman G, McGuire T, Turpin E, Libow J, et al. Central nervous system preventive therapy with systemic high dose methotrexate versus cranial radiation and intrathecal methotrexate: longitudinal comparison of effects of treatment on intellectual function of children with acute lymphoblastic leukemia. Proc Am Soc Clin Oncol 1987;6:158.
22. Brouwers P, Moss H, Reaman G, McGuire T, Turpin E, Libow J, et al. Central nervous system preventive therapy with systemic high dose methotrexate versus cranial radiation and intrathecal methotrexate: comparison of effects of treatment on academic achievement in children with acute lymphoblastic leukemia. Proc Am Soc Clin Oncol 1988;7:176.
23. Mulhern RK, Kovnar E, Langston J, Carter M, Fairclough D, Leigh L, et al. Long-term survivors of leukemia in infancy: factors associated with neuropsychologic status. J Clin Oncol 1992;10:1095-102.
24. Bleyer WA, Sather HN, Nickerson HJ, Coccia PF, Finklestein JZ, Miller DR, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol 1991;9:1012-21.
25. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: an overview of 42 trials involving 12,000 randomized children. Lancet 1996;347:1783-8.
26. Marten AF, Best KM, Garmezy N. Resilience and development: contributions from the study of children who overcome adversity. Dev Psychopathol 1990;2:425-44.
27. Cohen S, Parmelee AH. Prediction of five year Stanford-Binet scores in preterm infants. Child Dev 1983;54:1242-53.
28. Whitt JK, Wells RJ, Lauria MM, Wilhelm CL, McMillan CW. Cranial radiation in childhood acute lymphocytic leukemia: Neuropsychologic sequelae. Am J Dis Child 1984;138: 730-6.